Abstract| Volume 23, ISSUE 10, SUPPLEMENT , S49, October 2017

The Usefulness of Serial 18F-FDG PET/CT for Assessing Therapeutic Response in Cardiac Sarcoidosis with Ventricular Tachycardia

      Background: The assessment of 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) is a valuable diagnostic tool in the evaluation of cardiac sarcoidosis in recent years. However, the clinical value of serial quantitative 18F-FDG PET/CT to monitor the disease activity of cardiac sarcoidosis is still unknown. Case Report: We report a case of a 50-year-old woman suffered from incessant polymorphic ventricular tachycardia (VT). Continuous injection of amiodarone and landiolol reduced sustained VT and further cardiac assessment became feasible. In the first 18F-FDG PET/CT imaging showed focal cardiac uptake pattern in the septal and inferior wall of left ventricle. Gadolinium-enhanced cardiovascular magnetic resonance also showed delayed enhancement in the same cardiac segments. Immediately after these cardiac imaging, 30 mg/day of corticosteroid therapy started and the incessant polymorphic VT was successfully controlled. Daily dose of corticosteroid was gradually reduced to 10 mg and implantable cardioverter-defibrillator (ICD) implantation underwent 16 weeks after hospitalization. In the second 18F-FDG-PET/CT imaging, no 18F-FDG uptake was found in the whole ventricle. The patient has done well with no recurrence of VT and any ICD shocks during 18 months follow-up period. Conclusion: The present case indicated that serial 18F-FDG-PET/CT is feasible to determine the extent of disease activity and to quantitatively assess the response of cardiac sarcoidosis to therapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect